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Abstract
Background: Cerebral metastases are a common cause of death in patients with melanoma. Systemic drug
treatment of these metastases is rarely effective, and where possible surgical resection and/or stereotactic
radiosurgery (SRS) are the preferred treatment options. Treatment with adjuvant whole brain radiotherapy (WBRT)
following neurosurgery and/or SRS is controversial. Proponents of WBRT report prolongation of intracranial control
with reduced neurological events and better palliation. Opponents state melanoma is radioresistant; that WBRT
yields no survival benefit and may impair neurocognitive function. These opinions are based largely on studies in
other tumour types in which assessment of neurocognitive function has been incomplete.
Methods/Design: This trial is an international, prospective multi-centre, open-label, phase III randomised controlled
trial comparing WBRT to observation following local treatment of intracranial melanoma metastases with surgery
and/or SRS. Patients aged 18 years or older with 1-3 brain metastases excised and/or stereotactically irradiated and
an ECOG status of 0-2 are eligible. Patients with leptomeningeal disease, or who have had previous WBRT or
localised treatment for brain metastases are ineligible. WBRT prescription is at least 30 Gy in 10 fractions
commenced within 8 weeks of surgery and/or SRS. Randomisation is stratified by the number of cerebral
metastases, presence or absence of extracranial disease, treatment centre, sex, radiotherapy dose and patient age.
The primary endpoint is the proportion of patients with distant intracranial failure as determined by MRI
assessment at 12 months. Secondary end points include: survival, quality of life, performance status and
neurocognitive function.
Discussion: Accrual to previous trials for patients with brain metastases has been difficult, mainly due to referral
bias for or against WBRT. This trial should provide the evidence that is currently lacking in treatment decision-
making for patients with melanoma brain metastases. The trial is conducted by the Australia and New Zealand
Melanoma Trials Group (ANZMTG-study 01-07), and the Trans Tasman Radiation Oncology Group (TROG) but
international participation is encouraged. Twelve sites are open to date with 43 patients randomised as of the 31st
March 2011. The target accrual is 200 patients.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12607000512426
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Background
The incidence of central nervous system (CNS) metas-
tases in patients with metastatic melanoma ranges from
10% to 40% in clinical studies[1] and is even higher in
autopsy series, with as many as 72% of patients with
metastatic melanoma having CNS involvement [2].
Local control of brain metastases from melanoma is a
significant problem. Sampson et al. reported an overall
median survival time of 3.8 months in 702 patients with
clinically significant melanoma brain metastases, treated
with either palliative chemotherapy, radiotherapy or sur-
gery [3]. These metastases contributed to the death of
94.5% of these patients.
As well as seeking to prolong survival, maintaining
neurocognitive function in these patients is pivotal to
their quality of life. The clinically apparent metastases
can often be treated locally by neurosurgery and/or
stereotactic radiosurgery (SRS), with the option of post-
operative whole brain radiotherapy (WBRT). The objec-
tive of WBRT in this setting is to treat clinically unde-
tectable micrometastases elsewhere in the brain; these
are considered likely to be present in many patients and,
if not controlled, will later manifest as distant intracra-
nial treatment failure. However the role of WBRT after
local treatment is controversial. Proponents say that
WBRT to prevent or delay intra-cranial disease recur-
rence provides worthwhile palliation. Opponents argue
against WBRT as a survival benefit has never been
demonstrated in this situation and there is a risk of neu-
rotoxicity. These opinions are based on studies in other
malignancies, predominantly non small-cell lung cancer
and lymphoma, and retrospective analyses [4-7]. There
have been no randomised clinical trials (RCTs) for this
specific scenario in patients with metastatic melanoma.
A complicating factor is that there exists a strong anec-
dotal impression among some clinicians that melanoma
is a uniformly radioresistant tumour, although there is
no level 1 clinical evidence for this. As a result, current
clinical practice varies widely, with some units actively
encouraging WBRT while others rarely or never offer it.
In a randomised controlled trial of 95 patients with a
variety of solid tumour types who received WBRT fol-
lowing surgical excision of brain metastases, those
receiving WBRT (50.4 Gy over 5 weeks) had a 52%
reduction in intracranial recurrence and a 30% reduc-
tion in death from neurological causes compared to
those randomised to observation [4]. Although the time
to intracranial recurrence was substantially longer in the
WBRT group (220 weeks versus 26 weeks, p = < 0.001),
the median overall survival was not significantly differ-
ent between the two groups (11 months versus 10
months, p = 0.39), probably because a high proportion
of patients in both groups had extra-cranial disease.
A second randomised controlled trial comparing SRS
plus WBRT (30 Gy in 10 fractions) versus SRS alone in
132 patients with 1-4 brain metastases reported a 30%
reduction in local intracranial recurrence and a 22%
reduction in distant intracranial recurrence at 12 months
in the WBRT group (p = 0.001) [6]. There was no
difference between the groups in overall survival
(7.5 months versus 8 months) or neurological death.
In a subset of patients neurological toxicity and neurolo-
gical function were assessed radiologically and using the
Karnofsky Performance Scale (KPS) and the Mini
Mental State Examination (MMSE). There were no
significant differences in toxicity or function.
A more recent randomised trial undertaken by the
European Organisation for Research and Treatment of
Cancer (EORTC) comparing adjuvant WBRT (30 Gy in
10 fractions) to observation after surgery or radiosurgery
of 1-3 brain metastases (predominantly from lung,
breast and kidney cancer) assessed the time to func-
tional decline (performance score > 2) [8]. Overall survi-
val was similar in the WBRT and observation arms
(median 10.9 versus 10.7 months), however WBRT
reduced the 2-year relapse rate both at both initial sites
(surgery: 59% to 27%, p = 0.001; SRS: 31% to 19%, p =
0.040) and at new sites (surgery: 42% to 23%, p = 0.008;
SRS 48% to 33%, p = 0.023).
There has been some recent controversy about
whether WBRT affects neurocognitive function [9,10].
Assessment of neurocognitive function and health-
related quality of life (HRQOL) are essential for the
interpretation of WBRT in the context of the patient’s
experience. It is clear that tools such as the MMSE,
whilst appealing in their simplicity, were developed to
screen for dementia and show poor sensitivity in detect-
ing cognitive impairment in patients with brain tumours
[11]. The ideal tool should be brief, simple, sensitive,
inexpensive and, if administered repeatedly, should have
alternative versions to reduce the effects of learning
[12]. A battery of tests which fit these criteria (including
Hopkins Verbal Learning Test-Revised, Controlled Oral
Word Association of the Multilingual Aphasia Examina-
tion, Trail Making Test, Stroop Color-Word Test and
the Digit Span test) have been shown to be feasible in
previous clinical trials in patients with brain metastases
[13].
The European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) has been validated in numerous malignancies
including neurological malignancies [14,15] and mea-
sures five functional domains as well as global quality of
life and symptoms of fatigue, nausea, pain, dyspnoea,
insomnia, appetite loss, constipation, diarrhoea, and
financial difficulties. The EORTC BN-20 is a brain
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cancer-specific module that measures four multi-item
domains (future uncertainty, visual disorder, communi-
cation deficit, and motor dysfunction) [15]. A change in
scores of ≥ 10 on a scale of 0-100 persisting for 4 or
more weeks has been shown to represent a clinically
meaningful and subjectively significant change that is
associated with change in disease status [15]. These
tools are considered appropriate, validated and sensitive
in this population.
Using magnetic resonance imaging (MRI) as the pri-
mary means of assessment, the current trial will investi-
gate whether WBRT following complete local treatment
of intracranial melanoma metastases improves distant
intracranial control and hence demonstrate whether
radiotherapy in this scenario can control microscopic
intracerebral melanoma. If so, then it may contribute to
more clinically meaningful outcomes such as increased
time to functional decline from further intracranial dis-
ease or neurological death, without causing excessive
neurotoxicity. Trial recruitment will be supported
through referrals from multi-disciplinary melanoma
teams. The trial will be offered to all eligible patients in
whom intracranial disease control has been obtained by
complete surgical resection and/or SRS.
Objectives
This study aims to assess the value of treating brain
metastases in patients with AJCC stage IV melanoma
using adjuvant post-operative WBRT in the hope of
improving disease control, and quality of life, while
maintaining satisfactory cognitive performance. The pri-
mary objective is to assess the effect of WBRT (after
localised treatment for melanoma brain metastases) on
distant intracranial control, as assessed by MRI scan-
ning. (Figure 1) Distant intracranial control is defined as
control within the brain 1 cm or more from a previous
metastasis. The primary hypothesis is that as a result of
whole brain radiotherapy, there will be a 20% reduction
in the rate (proportion) of distant intracranial metastases
after at least 12 months of follow-up, compared to the
control (observation only) arm.
The secondary objectives are to assess the effect of
WBRT on:
1. Time to intracranial failure (local, distant and
overall (local+ distant)) as assessed by MRI




6. Death from neurological causes
Deterioration in neurocognitive function and distant
intracranial failure will be assessed for the following
subgroups: one versus more than one treated cerebral
metastasis; presence of extracranial disease versus none;
< 65 years of age versus ≥65 years of age.
Methods/Design
Trial Design
This trial is an international multi-centre, open-label,
stratified, 2-arm randomised phase III trial. Patients will
be randomised 1:1 to WBRT or observation. The trial
has been approved by the Cancer Institute NSW Clinical
Research Ethics Committee #2007C/11/032 and relevant
hospital ethics committees in each participating centre.
Participants
Patients will be recruited mainly from participating
multi-disciplinary melanoma treatment centres.
Patients will be identified through routine scanning
showing asymptomatic metastases or by investigation
of intracranial symptoms. The eligibility criteria are
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Figure 1 Trial schema.
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In order to be eligible, patients must meet all of the
specified inclusion and exclusion criteria. In addition,
patients will be excluded from the neurocognitive func-
tion (NCF) and quality of life aspects of the study if
their fluency of oral and written English is less than
Year 8 standard. Centres in countries where English is
not a main language can still participate in the primary
endpoint of the study but not the NCF component.
Setting
Melanoma treatment centres and tertiary cancer hospi-
tals with facilities for WBRT.
Interventions
Neurosurgery for melanoma brain metastases
Neurosurgery will be conducted according to the usual
practice at the treating centre. A lesion will be deemed to
be completely excised if the treating neurosurgeon reports
complete excision. A patient with a lesion not completely
excised should be referred for SRS Incomplete excision is
not an exclusion criterion; patients whose lesions are not
completely excised may still be randomised into the trial
to receive WBRT or observation. Histopathology reports
using hematoxylin and eosin stains as well as immunos-
tains (at least one of S100 or HMB45) are required.
Stereotactic radiosurgery (SRS) of melanoma brain
metastases
SRS may be given to the target lesion(s) definitively or
to the surgical cavity(ies) post resection. It should be
given according to the usual practice at the treating cen-
tre. Full records of the procedure need to be included in
the written SRS report. For quality assurance purposes,
copies of the prescription page and computer dosimetry
on axial, coronal and sagittal planning CT images
through the target(s) are required.
Control intervention
Observation only (no WBRT) with regular assessment of
outcomes at the same time points specified for the
intervention arm.
Assessment of Outcome
The primary endpoint of the study will be the propor-
tion of patients with distant intracranial failure (as
determined through MRI assessment) at 12 months.
Distant intracranial failure is defined as new lesions
appearing 1 cm or more from a previous index metasta-
sis. New onset leptomeningeal disease after the rando-
misation MRI will be recorded as new distant
intracranial disease. Patients who fail locally only will
not be considered as having an event and their time will
be measured from randomisation to their last known
follow-up date. Patients progressing or dying from extra-
cranial disease or other causes will be considered as
having a competing risk for distant intracranial failure.
The secondary endpoints include:
(i) Time to distant intracranial failure as determined
by MRI. This is defined as the time from the date of
randomisation to recurrence of disease at a distance
of 1 cm or more from previously treated metastases.
In the absence of distant intracranial failure (i.e. for
patients censored before intracranial failure could be
observed), time to failure will be measured from ran-
domisation to date of last known contact (i.e. cen-
soring time).
Table 1 Eligibility criteria - inclusions and exclusions
Inclusion criteria Exclusion criteria
• One to three (1-3) intracranial metastases on MRI from melanoma, all
locally treated with either surgical excision and/or stereotactic
irradiation. (It will be assumed that the metastases are melanoma if
the patient has documented histological or radiological concurrent
extracranial disease that has already categorised the patient as stage
IV). If the cerebral lesion(s) is/are the first presentation of stage IV
disease, then one metastasis must be histologically proven to be
melanoma for the patient to be included in the study.
• Life expectancy of at least 6 months.
• Aged 18 years or older.
• WBRT must begin within 8 weeks of completion of local treatment
and within 4 weeks of randomisation.
• Able to have an MRI brain scan with contrast enhancement.
Estimated glomerular filtration rate (eGFR) is adequate at the discretion
of the radiologist and capable of having gadolinium-containing
contrast medium for MRI (as per practice guidelines).
• Localised treatment of all brain metastases no more than 6 weeks
prior to randomisation.
• An ECOG performance status of 0, 1 or 2 at randomisation.
• CT scan of chest, abdomen and pelvis within 12 weeks of
randomisation.
• Serum lactate dehydrogenase (LDH) must be ≤ 2 times upper limit
of the participating centre’s reference range.
• Able to provide written informed consent.
• Any untreated intracranial disease.
• Any previous intracranial treatment (surgical excision and/or
stereotactic irradiation treatment and/or WBRT) prior to this
diagnosis of intracranial melanoma.
• Evidence of leptomeningeal disease on pre-local treatment MRI
scan.
• Patients with prior cancers, except: those diagnosed more than
five years ago with no evidence of disease recurrence within this
time; successfully treated basal cell and squamous cell skin
carcinoma; or carcinoma in-situ of the cervix.
• A medical or psychiatric condition that compromises ability to
give informed consent or complete the protocol.
• Positive urine pregnancy test for women of childbearing
potential.
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(ii) Time to local intracranial failure as determined
by MRI. This is defined as the time from the date of
randomisation to recurrence of disease within 1 cm
of previously treated metastases.
(iii) Time to overall (distant + local) intracranial fail-
ure as determined by MRI.
(iv) Deterioration in neurocognitive function (NCF).
This is measured by a battery of assessments includ-
ing Hopkins Verbal Learning Test, Controlled Oral
Word Association Test, Trail Making Test Part A
and B, Stroop Color-Word Test (Adult Version),
Digit Span (Forwards and Backwards). The propor-
tion of patients completing neurocognitive function
assessments at the baseline visit and at each 2-
monthly follow up visit will be determined for each
of the treatment groups (WBRT and Observation)
together with a descriptive summary of Global Defi-
cit Scores (GDS) scores. The main neurocognitive
function endpoint will be defined as the proportion
of patients who have deteriorated from the baseline
visit at any time in the study period by at least 0.3
units on the GDS scale.
(v) Time to deterioration in health related quality of
life. This is measured by EORTC QLQ-C30 with
Brain module (EORTC BN-20) questionnaires. The
completion rates for quality of life questionnaires at
the baseline visit and at each 2-monthly follow-up
visit will be determined for each treatment group
together with descriptive summaries of scores. The
primary QOL endpoint will be time to deterioration
in role function from randomisation, with deteriora-
tion defined as a decrease of ≥ 10 points on a 0-100
scale persisting for at least 4 weeks. Secondary end-
points will be time to deterioration in global QOL,
drowsiness, communication difficulties, motor dys-
function and social function items/domains.
(vi) Time to deterioration in performance status as
measured by ECOG criteria. This is defined as the
time that elapses between randomisation and the
first recorded worsening (increase) in ECOG perfor-
mance status.
(vii) Overall survival. This will include time to death
due to any cause; time to death due to a neurological
cause; cause of death (cancer related or not); and
cause of death if cancer related, due to neurological
progression or not. Overall survival will be assessed
from date of randomisation to date of death from any
cause. Patients remaining alive or lost to follow-up
will be censored at the date of last known contact.
Sample size
It has been assumed on the basis of previous studies[4,6]
that the proportion of patients having distant
intracranial metastases at 12 months post-randomisation
will be 55% in the observation arm (surgery and/or SRS
only) and 33% in the WBRT arm. With 200 patients
and assuming 10% non-adherence, this study will have
80% power to detect an absolute risk reduction of 22%
at the 5% significance level (two-tailed). To achieve a
total sample of 200 patients, it is assumed that patients
will be accrued over five years. This assumes a uniform
accrual rate of 40 patients each year, which will require
participation from international centres as well as cen-
tres in Australia and New Zealand.
Interim analyses and stopping guidelines
An independent data safety monitoring committee
(DSMC) will regularly monitor the occurrence of serious
clinical events. One formal efficacy analysis will be per-
formed after 45 events have been observed (the expected
number of events after 100 randomised patients have
completed 12 months of follow-up). The events used for
this formal interim analysis will be distant intracranial
failure after 12 months of follow-up. The stopping rule
for the study on the basis of efficacy will be a nominal
significance level of p = 0.003 (3 standard deviations) to
maintain an overall Type I error probability of 5%.
The DSMC will monitor the trial for safety outcomes
including unacceptable acute radiotherapy toxicity (any
Grade 4 toxicity); accrual less than 30% of the expected
number of patients within the first 36 months; and the
availability of a therapy that is clearly more effective.
Randomisation
Sequence generation and allocation concealment
mechanism
Randomisation will be performed by a centralised trial
coordinating centre using an interactive voice response
system (IVRS). Authorised staff from the participating
centres will submit eligible patients for randomisation.
Randomisation will be stratified by centre, gender, age,
number of cerebral metastases, presence of extracranial
disease and planned WBRT dose using minimisation.
Blinding
Study participants and treating clinicians will not be
blinded to treatment allocation. The centralised person-
nel assessing MRI scans and neurocognitive function
will be blinded to treatment allocation.
Statistical methods
Efficacy analyses will be conducted on the basis of
‘intention to treat’ and toxicity analyses will be by treat-
ment received and unadjusted. All comparisons will be
2-tailed with a 5% significance level. The primary end-
point, proportion of patients with distant intracranial
failure, will be compared for the two groups using chi-
squared or exact tests [16]. Continuous outcomes will
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be analysed by using t-tests or suitable non-parametric
methods if appropriate. The secondary endpoint, time to
distant intracranial failure, will be compared for the two
groups using the logrank test and Kaplan-Meier curves
[16]. Exploratory analyses will be conducted adjusting
for prognostic factors using proportional hazards or
other suitable regression models. Other time-to-event
endpoints will be analysed using similar methods.
Subgroup analyses
Deterioration in neurocognitive function and distant
intracranial failure will be assessed for the following
subgroups: one versus more than one cerebral metasta-
sis; presence of extracranial disease versus none; patients
< 65 years of age or ≥65 years of age. Other outcomes
assessed for the main study will also be analysed for the
subgroups with the acknowledgement that these ana-
lyses are exploratory and hypothesis-generating.
Quality Assurance
Radiotherapy treatment delivery
Technical review for all patients who undergo WBRT
will be conducted by the Trans-Tasman Radiation
Oncology Group (TROG). Figure 2 provides an
example of WBRT simulation, planning and treat-
ment volume. Sites must submit copies of the case
history, treatment prescription, treatment administra-
tion sheet, dosimetry plans and portal verification
films.
Radiological audit of MRI scans
At least 25% of the patients will be audited, including
the first 5 patients from each centre and a randomly
selected patient from each subsequent 5 patients. Audit-
ing will include an evaluation of MRI technique. The
audit will be performed by a central radiologist with
specialisation in MRI neuroradiology, with reference to
a second central radiologist, similarly qualified, at the
central radiologist’s discretion. This second central radi-
ologist will be blinded to the local and central radiolo-
gists’ reports.
Operational considerations
Patients who are randomised to the observation arm of
the study and have a recurrence of brain metastases will
be able to crossover to WBRT at the treating physician’s
Figure 2 Plain simulation film showing isocentre on the caudal edge of the field to ensure that there is no divergence through the
contralateral eye. WBRT Quality Assurance. Simulation & Planning. The patient must be simulated supine, arms by the side, head resting on
neck-shape as per department protocol. A personalised immobilisation mask can be used. Treatment Volume. The fields must cover the whole
brain and include the cerebrum and cerebellum. The superior border of the field must be overshooting the skull by 2 cm to ensure adequate
coverage. There must be adequate coverage of the intracranial contents by a margin of 1-2 cm. The caudal border needs to be angled to
accomplish this and also avoid the eyes. The pituitary is usually included in the field by default. No effort should be made to cover it if it is not
in field.
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discretion. All participants will be monitored to death or
to the closure of the trial.
Discussion
Feasibility
The possibility of conducting this trial was first dis-
cussed at a multi-disciplinary melanoma meeting in Syd-
ney in 2004. A previous trial of WBRT for solitary brain
metastases from mixed tumour types was abandoned by
another Australian/New Zealand study group due to
failure to accrue sufficient participants (TROG 98.05)
[17]. Given this background and the concern from some
investigators about future WBRT trials, a feasibility
study was undertaken to assess not only the number of
potentially eligible patients but also the willingness of
surgical and medical oncologists to have their patients
with melanoma randomised to WBRT or not. The trial
protocol was presented and critiqued at numerous
scientific meetings both nationally and internationally,
to multi-disciplinary melanoma treatment centres, and
to neuro-oncology groups. There was broad agreement
that the trial was needed to answer several fundamental
questions and international participation was deemed
essential for recruitment success. At present there are
three participating countries: Australia, Norway and the
United Kingdom. As of the 31st March 2011, 43
patients were randomised with 30 of these completing
the neurocognitive function assessment.
Registration
This trial is registered with the Australia and New
Zealand Clinical Trials Registry (ANZCTR) #
ACTRN12607000512426
Protocol
A full copy of the current protocol can be requested
from the principal investigator: Dr Gerald Fogarty,
email: gerald.fogarty@cancer.com.au
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